Normal Ovarian Reserve During Long‑Term Osimertinib Therapy in a Patient With Li‑Fraumeni Syndrome
Osimertinib treatment for 36 months does not diminish ovarian reserve in a patient with Li‑Fraumeni syndrome and non‑small cell lung cancer.
In contrast to the well‑studied gonadotoxicity of traditional chemotherapy, data on the long‑term effects of newer targeted molecular therapies on human ovarian reserves and fertility remain scarce. Here, we report the effect of osimertinib on ovarian reserve. Osimertinib is a third‑generation, irreversible tyrosine kinase inhibitor that selectively targets epidermal growth factor receptor (EGFR)–mutant tumors and is used to treat EGFR‑positive non‑small cell lung cancer (NSCLC). We present a 30‑year‑old woman with a history of Li‑Fraumeni syndrome (LFS), NSCLC, and a large fumarate hydratase‑deficient uterine fibroid who was referred for fertility counseling and preservation while receiving maintenance osimertinib. Ovarian reserve was assessed using anti‑Müllerian hormone (AMH) measurements and serial pelvic ultrasounds to determine the antral follicle count. Monitoring over 36 months of osimertinib therapy showed a normal ovarian reserve, as evidenced by normal AMH levels and a stable antral follicle count. We demonstrate a normal ovarian reserve in a patient receiving long‑term osimertinib treatment.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT